Last reviewed · How we verify

GBS trivalent vaccine — Competitive Intelligence Brief

GBS trivalent vaccine (GBS trivalent vaccine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Influenza vaccine, RSV vaccine, Hib vaccine. Area: Vaccines.

phase 2 Influenza vaccine, RSV vaccine, Hib vaccine Vaccines Biologic Live · refreshed every 30 min

Target snapshot

GBS trivalent vaccine (GBS trivalent vaccine) — GlaxoSmithKline. Stimulates the immune system to produce antibodies against the influenza virus, RSV, and Hib.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GBS trivalent vaccine TARGET GBS trivalent vaccine GlaxoSmithKline phase 2 Influenza vaccine, RSV vaccine, Hib vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Influenza vaccine, RSV vaccine, Hib vaccine class)

  1. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GBS trivalent vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/gbs-trivalent-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: